Company > Strategy
Acacia Pharma aims to become a leading hospital pharmaceuticals business selling products directly to anesthesiologists and oncologists in the US. The key elements of this strategy are:
Directly commercialize Barhemsys® and Byfavo® in the US through our own sales and marketing infrastructure.
Establish strategic partnerships for the commercialization of Barhemsys® and APD403 outside the US with companies that have local expertise and commercial infrastructure, initially focusing on the major pharmaceutical markets.
Leverage our US commercial infrastructure to sell APD403 for CINV to oncologists.
Consider the further in-licensing or acquisition of complementary products or product candidates that can be commercialized effectively through our US organization.